Full title: A Phase 2, Single Arm, European Multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in advanced chordoma
This study aims to find out how effective afatinib is as first-line or later-line treatment in advanced chordoma. Two groups of patients will be included: twenty first line patients and twenty second or further line patients. The treatment will be given in four week cycles until disease progression.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.